Background: Intensification of systemic therapy for high-risk neuroblastoma (HRNB) has resulted in improved local control and overall survival (OS) leaving potential for de-escalation of primary site radiotherapy. The utility of primary site de-escalation should be evaluated in the context of potential for successful local-regional salvage. We evaluated salvage strategies and outcomes in patients with HRNB with local-regional recurrence as a component of first failure.
INTRODUCTION
Up to 60% of children with high-risk neuroblastoma (HRNB) will experience disease progression within 18 months of frontline therapy. 1 At recurrence, therapeutic options are often limited given the intensity of initial therapy, high rate of multifocal distant recurrence, and limited response rates to salvage chemotherapy. 1 Studies detailing the role of local therapy including surgery and radiotherapy (RT) at recurrence are sparse, so clinicians must rely on their institutional experience and clinical judgment to decide who should have local-regional therapies used as a component of salvage. Several studies have evaluated alternative forms of RT in previously irradiated patients, such as intraoperative RT and stereotactic body RT (SBRT), for use at salvage either as re-irradiation or at new sites of disease. [2] [3] [4] Given that few studies have evaluated the utility of salvage RT as a component of local therapy in patients with HRNB with a component of local-regional relapse as first failure, we evaluated the outcomes and management strategies utilized in a cohort of patients with HRNB treated on prospective trials with varying intensities of frontline systemic therapy who had local-regional relapse as a component of first failure.
METHODS

Patient population and data abstraction
This study was reviewed and approved in accordance with the policies of the institutional review board of St. Jude Children's Research Hospital. We identified 20 patients with locoregional recurrence with or without concomitant distant failure after initiating frontline therapy among 89 consecutively treated patients with HRNB, according to Children's Oncology Group (COG) risk stratification criteria, between 1997 and 2013. Patient characteristics including initial treatment, disease characteristics, salvage therapy, and outcomes were abstracted from the electronic medical record. Paper records were reviewed if the electronic record had insufficient information. Disease progression was determined by using patient diagnostic imaging, radiology reports, and physician notes. Local and regional failures were defined according to the initial extent of disease. A local failure was defined as a failure at the primary site or attached lymph nodes if the two masses were readily indistinguishable. Regional failures were defined as discontiguous nodal failures within a regional draining nodal basin.
Analysis of imaging and radiation records
When available, computed tomography (CT), magnetic resonance imaging (MRI), metaiodobenzylguanidine (MIBG), and/or 99mTc-methylene diphosphonate bone scans from diagnosis, postinduction, immediately prior to surgery, post-transplant, and treatment failure were coregistered for each patient and merged with the patient's RT treatment plan by using MIM (v6.7.6, MIM Software Inc.). Disease volume co-incidence and extent of disease were rendered in three dimensions for anatomic review to better understand local-regional spread and the use of RT at salvage (Figure 4 ).
Statistical methods
All data were stored in institutional databases and extracted for management in Excel 2013 (v15.0.4963.1000, Microsoft Corporation).
Nonparametric descriptive measures of central tendency were used to describe the patient, disease, and treatment characteristics. All timeto-event calculations were described by using the Kaplan-Meier estimator. Time to progression was defined as the time from first failure to any cancer-related event or death. Time to death was defined as the time from first failure to death. SAS (v9.3, Cary, NC) and R studio (1.1.383) were used for all statistical procedures.
RESULTS
Patient characteristics
Patient characteristics are summarized in 
Initial treatment at diagnosis
Initial treatment at diagnosis comprised a combination of induction chemotherapy, surgery, radiation therapy, and myeloablative chemotherapy with autologous stem cell support. Frontline therapy was per protocol, as indicated in Table 1 . Details regarding the extent of initial therapy have been previously described. [5] [6] [7] [8] [9] [10] In brief, induction chemotherapy was administered to reduce bulk tumor volume. Surgical timing for primary tumor resection was varied but was completed at any time from diagnosis to immediately following induction chemotherapy. Thirteen of the patients in the study had a gross or near total resection at diagnosis, while seven had a subtotal resection at diagnosis. Following chemotherapy and surgery, patients A, amplified; Abd, abdomen; ABT-751, oral antimitotic sulfonamide therapy; Adj., adjuvant; Adr, adrenal; AWD, alive with disease; AWOD, alive without disease; CAE, cyclo/adriamycin/etoposide; cis RA, retinoic acid; Cyclo, cyclophosphamide; DOD, died of disease; DOT, died of treatment; Dx, diagnosis; DX8951f, exatecan mesylate; Etop, etoposide; F, favorable; GD2NK; anti-GD2 antibody and NK-cell therapy; GTR, gross tumor resection; HR, hazard ratio; ICE, ifosfamide, carboplatin, and etoposide; 1o, primary tumor; Irin, irinotecan; L, local-only failure; (L, D), local failure with concurrent distant failure; (L, R), local-regional failure; MIBG,
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I-meta-iodobenzylguanidine; N, not-amplified; P, pelvis; Post, posterior; R, regional-only failure; (R, D), regional failure with concurrent distant failure; RT, radiotherapy; Sup, superior; TMZ, temozolomide; Topo, topotecan; Tx, treatment; U, unfavorable, Unk, unknown; Vincr, vincristine; 13-cis RA, isotretinoin.
F I G U R E 1 Sankey diagram depicting pertinent management of patients who experienced local-regional failure. Data were extracted from the electronic medical record of 20 patients (median age, 34 months; range, 16 months to 16 years) with high-risk neuroblastoma who experienced recurrence on prospective trials from 1997 to 2013. Initial therapy was induction chemotherapy, surgery, and myeloablative chemotherapy with autologous stem cell support; 14 patients underwent 19 salvage radiotherapy courses to either the primary or metastatic sites. Surgery was used selectively in four patients who had either local-only or regional-only failure at initial recurrence. AWD, alive with disease; AWOD, alive without disease; Chemo, chemotherapy; DF, distant failure; DOD, died of disease; DOT, died of treatment; LF, local failure; LRF, local-regional failure; RF, regional failure; RT, radiotherapy; Surg, surgery
Extent of recurrence
The extent of disease at relapse was variable. Extent of disease at failure was as follows: two local only, four regional only, four local-regional (LRF), five combined local or regional and distant, and five combined local, regional, and distant failure (Table 1, Figure 1 ).
Salvage therapy
Treatment at failure consisted of varying combinations of chemotherapy, RT, surgery, and transplant ( Figure 1 ). The most common recurrence site was within the abdomen along the para-aortic lymph node chain (three of 20 patients) ( Table 1) . Surgery was used selectively in four patients having local-only or regional-only failure at initial recurrence. Eighteen patients received one or more chemotherapy regimens following relapse (Table 1) . Most patients in our series were managed with ifosfamide, carboplatin, and etoposide (ICE) at relapse, although some were treated with irinotecan plus temozolomide (IT).
The remaining patients in our study were managed with more conventional salvage therapy regimens (cyclophosphamide/topotecan). Four patients were treated on prospective trials at relapse. [11] [12] [13] [14] Anti-GD2 monoclonal antibody was used at salvage in one patient. 15 One patient obtained salvage with 131 I-MIBG therapy at an outside hospital.
Fourteen patients in our final cohort who were irradiated as part of their salvage treatment strategy underwent a combined total of 19 salvage RT courses to the primary and/or metastatic sites. Only one patient received repeat RT to an initially irradiated site of disease for an infield relapse (Figure 1 ). This patient experienced minimal toxicity (<grade 3) and is alive without disease (NB10, Table 1 ). Extended patient timelines detailing the salvage therapy course are shown in Supplementary Figure S1 .
F I G U R E 2 Survival probability after HRNB recurrence stratified by extent of relapse. Median follow-up: 13 years (range, 0.9-25.2 years). At the last follow-up, six patients (one local-only, two regional-only, one local-regional failure, one local-only with concurrent distant, and one local-regional failure with concurrent distant failure) were alive following salvage therapy. Patients treated with RT at LRF had survival comparable to that of those who received RT during initial therapy. The time to LRF was 8.7 months in those who received planned adjuvant RT after autologous stem cell transplant and 14.6 months in those who received no RT after transplant
Outcomes
After a median follow-up time of 13 years (range, 0.9-25.2 years), six patients with LRF were alive following salvage therapy ( Figure 1 , Table 1 ). Two patients died of complications related to therapy including complications related to prolonged myelosuppression. The median duration of chemotherapy prior to subsequent progression was 11 months (95% CI, 4.8-15 months). Among the 10 patients managed at relapse with combinations of RT ± surgery, ±chemotherapy, four were alive without disease at last follow-up. As shown in Figure 2 , median overall survival (OS) was 4.6 years (95% CI, 0.6 to not reached)
after LRF and 0.6 years (95% CI, 0.05-2.6 years) after LRF with distant failure (P = 0.03). 
Review of initial and failure treatment volume in relation to RT plan
Volumetric imaging documenting local and/or regional failure was available in five of 20 patients (Figure 4 ) while 15 patients' imaging data were stored as serialized MRI, CT, or bone scan axial images on a film sheet or were unavailable. RT target volumes encompassed disease at recurrence in three of the four cases shown while patient NB35 experienced a late out of field pelvic nodal relapse.
DISCUSSION
Use of local therapies at salvage in HRNB has been limited, given the propensity for multifocal metastatic disease and unclear data on its utility. We review outcomes of 20 patients with local and/or regional relapse managed with varied local control strategies and document successful salvage and durable disease control in a limited subgroup of patients with local/regional-only relapse.
Prognostic features at relapse in HRNB
Prognostic features at the time of diagnosis in patients with HRNB are well characterized; however, few studies have reviewed prognostic features at the time of relapse. Of the studies that have addressed OS after relapse, evidence has suggested that the time to first relapse, stage, MYCN amplification, MIBG scan scoring, and age at diagnosis are prognostic factors that impact OS. 16 While subset analyses are difficult in our limited cohort, we did observe an impact of the extent of disease at relapse (Figure 2) . We also observed a trend towards improved OS from first relapse in patients who experienced relapse >12 months from diagnosis, and for patients with Shimada favorable disease (Supplementary Figure S2) . A study conducted by the Children's Oncology Group sought to determine whether the time from diagnosis to first relapse was a significant predictor of OS using the International Neuroblastoma Risk Group database with over 2,000 patients who experienced first-time relapse. 16 The study determined that the risk of death is higher for patients whose disease relapses within 18 months after diagnosis, for those who are older at diagnosis, and for those with MYCN amplification. Thirteen of 20 patients in our cohort were initially treated on NB97, which has reduced intensity and cumulative doses of oxazophosphorine equivalents, adriamycin, and topotecan. The patients treated with more modern intensive induction and consolidation regimens (NB2005, NB2008, and NB2012) exhibited a trend toward reduced time to death from first relapse (Supplementary Figure S2 ). As a result, initial therapy intensity should be considered when weighing the potential utility of local therapy at salvage.
Impact of local treatment modalities at relapse
Prior reports have considered the use of alternative RT delivery strategies at salvage in both previously irradiated and nonirradiated patients. 3, 4, 17 While subset analyses are difficult in our limited cohort, we did observe an impact of measures used for local control of locoregional relapse (Figure 3 ). Other groups have observed similar findings regarding the use of RT at recurrence. One study investigated the F I G U R E 4 Patterns of treatment failure in patients with HRNB. Sufficient volumetric imaging was available for a proportion of patients to enable delineation of disease volumes during therapy and at failure in relation to initial and salvage RT dose. Top: Disease volumes. Bottom: RT-plan overlay. Bone, blue denim; gross tumor volume (GTV) at diagnosis, dark yellow; GTV postinduction/presurgery, lime green; GTV failure, red; RT dose, pink possible role of intraoperative radiation therapy after reresection of locally recurrent or refractory NB. 3 This study found that intraoperative radiation therapy after prior external beam RT had an acceptable toxicity profile, a favorable local control rate of 55% at 2 years, and possibly a prolonged OS in well-selected cases. 3 An additional study evaluated the use of another form of external beam RT, SBRT, in a child with HRNB following recurrence. 4 Although SBRT effectively controlled this patient's disease, it was not without significant toxicity. 4 The report suggests that further use of SBRT in previously irradiated children with refractory or recurrent HRNB should be investigated and approached with caution. Only one patient treated in our series had received a prior course of external beam RT and was retreated for an infield relapse. Toxicity was limited and the patient is alive without disease (NB10, Table 1 ).
Impact of systemic treatment modalities at relapse
The high metastatic failure rate in refractory and recurrent NB has led investigators to evaluate novel combinations of systemic therapy in the salvage setting. 18 Some data suggest that patients with refractory FDA approval for primary therapy. 15 Only one patient in our series was managed with anti-GD2 monoclonal antibody at relapse and is alive at present with stable disease. Others were not considered for this treatment regimen given that most were treated prior to the FDA approval of dinituximab. The remaining patients in our study were managed with more conventional salvage therapy regimens (cyclophosphamide/topotecan), now considered an inferior salvage chemotherapy regimen, but had prolonged survival at the time of relapse relative to more recent studies. 15 It remains unclear whether the intensity and cumulative doses of initial systemic therapy had a substantial impact on the prognosis at relapse, although patients managed on reduced intensity trials; for example, NB97 did show improved survival from the time of relapse (Supplementary Figure   S2 ). It is possible that the incorporation of more effective second-line therapy (IT ± dinituximab) at the time of first salvage in patients would lead to improved OS relative to the regimens selected for this analysis for those managed with more recent intensive systemic therapy regimens, which incorporate the use of tandem transplantation. 22 Prior studies have reported on the relevance of systemic therapy intensity to treatment outcomes and therapeutic response in the upfront setting. While Pearson et al. noted improved event-free survival in patients managed for dose-intense induction chemotherapy relative to standard induction chemotherapy, no gain in OS was reported. 23 No prior reports have investigated the impact of initial therapy intensity on prognosis at first relapse, and as such it remains unclear whether there is a trade-off between initial systemic therapy intensity and subsequent salvage rate with regard to prognosis. 24, 25 
CONCLUSION
Further investigation into maximizing the efficacy of the current modalities used to treat relapsing HRNB should continue to improve the current low survival rates. Our study demonstrates the potential efficacy of local control strategies at the time of local recurrence in patients with HRNB without concurrent distant failure. Local therapy combined with systemic therapy in well-selected patients with recurrent HRNB with delayed relapse (>12 months from diagnosis) and absence of systemic relapse may lead to improved clinical outcomes relative to those of patients who are managed with more intensive induction and consolidation regimens at diagnosis.
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